Telomir Pharmaceuticals’ Short Interest Surges 43.5% in October

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) experienced a substantial increase in short interest during October 2023, marking a notable shift in market sentiment. As of October 15, the total short interest reached **1,880,000 shares**, reflecting a **43.5%** increase from the **1,310,000 shares** reported on September 30. This represents approximately **13.0%** of the company’s total shares outstanding.

The short-interest ratio currently stands at **0.6 days**, based on an average daily trading volume of **3,050,000 shares**. This figure indicates a growing level of bearish sentiment among investors regarding the company’s future performance.

Current Stock Performance

Shares of Telomir Pharmaceuticals opened at **$1.41** on October 18, 2023. Over the past year, the stock has fluctuated, reaching a low of **$1.12** and a high of **$7.08**. The company holds a market capitalization of **$45.51 million** and has a price-to-earnings (P/E) ratio of **-2.61**, reflecting its current challenges in profitability. Furthermore, the stock’s beta is recorded at **-0.53**, suggesting lower volatility compared to the market.

In its most recent earnings report released on August 14, 2023, Telomir Pharmaceuticals reported an earnings per share (EPS) of **($0.17)**, which fell short of analysts’ expectations of **($0.08)** by **$0.09**. Analysts project that the company will post an EPS of **($0.40)** for the current fiscal year, indicating continued financial difficulties.

Hedge Fund Activity and Analyst Ratings

Recent activity among institutional investors reveals varied strategies regarding Telomir Pharmaceuticals. Notably, **HighTower Advisors LLC** established a new position in the first quarter valued at approximately **$139,000**. Additionally, **Bank of New York Mellon Corp** increased its stake by **26.4%**, bringing its total holdings to **91,353 shares** valued at **$295,000** after acquiring an additional **19,058 shares**. Other firms, including **Nuveen LLC**, **Marshall Wace LLP**, and **Jane Street Group LLC**, have also made new investments in the company, reflecting a mix of confidence and caution.

In terms of analyst ratings, **Weiss Ratings** reaffirmed a “sell (e+)” rating for Telomir Pharmaceuticals on October 8, 2023. Currently, one analyst rates the stock as a strong buy, another as a buy, while one has issued a sell rating. According to **MarketBeat.com**, the average rating for Telomir Pharmaceuticals is classified as “moderate buy,” with an average target price of **$15.00**.

Telomir Pharmaceuticals is focused on developing therapeutic treatments for human stem cells, with a particular emphasis on **TELOMIR-1**, a novel small molecule aimed at addressing age-related inflammatory conditions and health issues that arise post-chemotherapy. The company’s ongoing research and development efforts position it at a critical juncture as it seeks to navigate market challenges and enhance shareholder value.